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Colloidal gold (Au), a well-tolerated nanomaterial, is currently exploited for 
several applications in nanomedicine. We show that gold nanoparticles tagged
with a novel tumor-homing peptide containing Asn-Gly-Arg (NGR), a ligand of 
CD13 expressed by the tumor neovasculature, can be exploited as carriers for 
cytokine delivery to tumors. Biochemical and functional studies showed that the
NGR molecular scaffold/linker used for gold functionalization is critical for CD13
recognition. Using fibrosarcoma-bearing mice, NGR-tagged nanodrugs could 
deliver extremely low, yet pharmacologically active doses of tumor necrosis factor
(TNF), an anticancer cytokine, to tumors with no evidence of toxicity. Mechanistic
studies confirmed that CD13 targeting was a primary mechanism of drug delivery
and excluded a major role of integrin targeting consequent to NGR deamidation,
a degradation reaction that generates the isoAsp-Gly-Arg (isoDGR) integrin 
ligand. NGR-tagged gold nanoparticles can be used, in principle, as a novel





The efficacy of cytokines in cancer therapy is often 
limited by their toxicity and counter-regulatory 
mechanisms. For example, the anti-tumor activity of 
tumor necrosis factor-alpha (TNF), an inflammatory 
cytokine with potent anti-tumor activity, is limited by 
a prohibitive systemic toxicity and by the release of 
soluble TNF-receptors into the circulation that inhibit 
its anticancer activity [1]. We have previously shown 
that these limitations can be overcome, at least in the 
cases of TNF and interferon (IFN)-gamma, by 
administering extremely low amounts of cytokines 
fused to tumor vasculature-homing ligands, a strategy 
that enables “active” targeted delivery of pharma-
cologically relevant doses of cytokines to tumors [2–4]. 
One of these products, NGR-TNF, which consists of 
TNF fused to a tumor-homing disulfide-bridged pe-
ptide containing Asn-Gly-Arg (NGR), is now under 
investigation as an anticancer drug in phase II and III 
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clinical studies, with evidence of activity and good 
tolerability [1, 2, 5–7]. 
The therapeutic index of cytokines can also be 
increased by an alternative strategy based on cytokine 
coupling with colloidal gold, a well-tolerated nano-
material currently exploited for several applications 
in the field of nanomedicine [8, 9]. For example, the 
therapeutic index of TNF is significantly increased  
by coupling with 27-nm gold nanoparticles [10], a 
formulation that is being tested in cancer patients, 
with evidence of improved efficacy [11, 12]. The 
improved activity of nanogold-based drugs is likely 
dependent on “passive” targeting mechanisms owing 
to abnormally leaky vasculature in tumors, which 
leads to enhanced permeability and drug retention in 
neoplastic tissues [10].  
The combination of “active” and “passive” targeting 
mechanisms might represent an efficient strategy  
for improving the delivery of cytokines to the tumor 
vasculature, thereby reducing the cytokine dose 
necessary to induce pharmacological effects and 
minimizing the activation of counter-regulatory 
mechanisms. This could be achieved, in principle,  
by coupling gold nanoparticles with tumor-homing 
ligands selective for receptors that are overexpressed 
by tumor cells and/or vasculature. 
Disulfide-bridged NGR peptides (e.g., CNGRC) 
could be exploited for this purpose; they have been 
successfully used to deliver TNF, IFN-gamma, and 
IFN-alpha-2a to tumors [2, 3, 13] owing to their ability 
to recognize an aminopeptidase-N (CD13) form 
expressed by tumor vessels [14–16]. However, the 
sulfur atoms of these peptides may bind to gold, 
thereby altering or hindering the NGR structure. Thus, 
an alternative molecular scaffold of NGR is necessary. 
In this regard, a relevant issue is the potential impact 
of the scaffold on NGR stability and function. Indeed, 
consistent experimental evidence suggests that the NGR 
scaffold crucially affects asparagine (N) deamidation, 
a spontaneous degradation reaction that leads to  
the formation of aspartate (D) and isoaspartate (isoD). 
Remarkably, this reaction, which occurs in an unusually 
rapid manner in NGR peptides (e.g., the half-life   
of asparagine in CNGRC is 3–4 h) [17, 18], causes a 
change in function, as the transition from NGR to 
isoAsp-Gly-Arg (isoDGR) (but not to DGR) is accom-
panied by receptor switching from CD13 to integrins 
[17–20]. Biochemical studies, NMR structure analyses,  
and integrin-docking experiments have shown that 
isoDGR, but not NGR or DGR, can fit into the RGD- 
binding pocket of αvβ3, an integrin that is over- 
expressed in tumor vessels, recapitulating not only the 
canonical RGD/integrin contacts, but also establishing 
additional polar interactions [21]. Remarkably, isoDGR 
embedded in different molecular scaffolds have 
markedly different affinities for v3 and can bind 
other integrins, such as v5, v6, v8, and 51 
[17, 18, 21–23]. Even the linker used for peptide coupling 
to proteins can affect integrin binding [24]. Thus, the 
molecular scaffold and the linker of NGR might be 
crucial for peptide/gold interactions, peptide stability, 
NGR conformation, and CD13 recognition, as well  
as for the receptor binding properties of the NGR 
degradation products, with potentially important 
pharmacological and toxicological implications.  
Accordingly, we prepared various TNF/gold-based 
nanodrugs functionalized with peptides containing 
NGR (or its degradation product isoDGR) embedded 
in different scaffolds and characterized their functional 
properties and their therapeutic activity in experimental 
models. We show that gold nanoparticles tagged with 
a novel head-to-tail cyclic NGR peptide can be used 
as carriers for delivering extremely low doses of TNF 
to tumors, with evidence of activity. Furthermore, we 
provide evidence that the mechanism of action is 
primarily mediated by CD13 targeting, and not by 
integrin targeting consequent to isoDGR formation. 
2 Results 
2.1 Preparation and characterization of NGR and 
IsoDGR peptides 
We prepared new hexa- and epta-peptides (head-to- 
tail cyclized), called N1, N3, N4, and N5, containing 
NGR and a Cys residue with a free thiol group that 
enables peptide coupling to proteins or to nano-
particles by using maleimide-containing bifunctional 
cross-linkers (see Fig. 1 for a schematic representation). 
In parallel, we prepared two disulfide-bridged peptides 
(called NGR-2C and NGR-2C(Y)), and two isoDGR 
peptides corresponding to the main deamidation 
products of N1 and N3 (called Iso1 and Iso3) (Fig. 1), 
previously described [17, 18, 24], which can be used  
 www.theNanoResearch.com∣www.Springer.com/journal/12274 | Nano Research 
1395 Nano Res. 2016, 9(5): 1393–1408 
 
Figure 1 Schematic representation of NGR, isoDGR, and RGD 
peptides with different molecular scaffolds prepared by chemical 
synthesis. Amino acids are represented with the single letter   
code; SH, free thiol group; isoD, isoaspartate; r, D-arginine;     
f, D-phenylalanine. Peptide codes are reported within each structure. 
Arrows indicate the isoDGR deamidation products of N1 and N3.  
as positive controls in CD13 and integrin binding 
studies. Other control peptides, including a mutated 
form of N1 with D-Arg in place of L-Arg (called N1(r)) 
and a peptide with RGD in place of NGR (CRGDf, 
called RGD), all cyclic and with a free thiol, were also 
prepared (Fig. 1). A mass spectrometry analysis of 
each product showed molecular masses consistent 
with the expected values  (Table S1 in the Electronic 
Supplementary Material (ESM)). 
The capability of NGR peptides to recognize CD13 
was analyzed by enzyme inhibition and competitive 
binding assays. We observed that the peptides N1 
and N3 were the most efficient inhibitors and binders 
(Fig. 2(a) and Table S2 and Fig. S1 in the ESM). 
Noteworthy, while N3 inhibited CD13 with potency 
similar to that of NGR-2C(Y), a reference peptide,  
N1 was about 5–6-fold more efficient, pointing to an 
important role of the NGR molecular scaffold in CD13 
recognition. N4, N5, N1(r), and RGD caused little or no 
inhibition (Figs. 2(a) and 2(b)). Based on a steady-state 
enzyme kinetic analysis in the presence of various 
amounts of substrate and inhibitors, N1, N3, and 
NGR-2C affected the Michaelis constant (Km), but not 
the maximum velocity (Vmax) (Fig. 2(c)). The data were 
consistent with the competitive inhibition model (N1, 
Ki = 12.4 ± 5.4 μM; N3, Ki = 81.3 ± 12.1; NGR-2C, Ki = 
134 ± 28), suggesting that N1, N3, and NGR-2C bind 
within, or close to, the active site of the enzyme. 
To exclude the possibility that the differential binding 
properties of N1, N3, and NGR-2C(Y) were related to 
differential Asn deamidation (with consequent NGR- 
to-DGR/isoDGR transition and loss of affinity), we 
studied their deamidation kinetics. A mass spectrometry 
analysis of peptides before and after incubation in 
ammonium bicarbonate buffer, a condition known to 
promote rapid peptide deamidation, showed a 1-Da 
increase in the molecular mass of each NGR site after 
22 h of incubation (Fig. S2(a) in the ESM). As the 
transition of N to D/isoD causes the gain of 1 Da, these 
data suggest that all of the peptides were completely 
deamidated after incubation. Accordingly, a competitive 
binding assay to αvβ3 showed that fifty percent of the 
NGR-to-isoDGR transition occurred after approximately 
2 h of incubation for all peptides (Fig. S2(b) in the 
ESM), pointing to similar kinetics. Thus, the different 
affinities of these peptides to CD13 were not related 
to differential kinetics of Asn deamidation. More likely, 
they were related to the different scaffolds, which 
could affect the NGR structure or directly contribute 
to CD13 binding. The higher affinity of N1 (with G 
before NGR) compared to N3 and NGR-2C (both with 
C before NGR) suggests that a G/C change at this 
position markedly affects binding. In contrast, the 
similar affinity of N3 and NGR-2C (with G or C after 
NGR, respectively) suggests that the G/C change at 
this position is less important.  
The capability of N1, N3, Iso1, and Iso3 to recognize 
integrins was also characterized by an αvβ3-competitive 
binding assay. Micromolar concentrations of N1 
competed with the binding of a CisoDGRC-peroxidase 
conjugate to αvβ3 (EC50: 10 μM) (Fig. S3 in the ESM). 
The apparent binding was likely indirect and related 
to the formation of a small amount (0.1%) of isoDGR 
during the assay, as Iso1 inhibited binding at 1,000- 
fold lower concentrations (EC50: about 10 nM). Similar 
results were obtained with N3 and Iso3 (Fig. S3 in  
the ESM). 
2.2 Preparation and characterization of NGR- and 
IsoDGR-albumin conjugates 
The peptides N1 and N3 and the corresponding Iso1 
and Iso3 deamidation products were selected for 
gold functionalization. Given the capability of gold 
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nanoparticles to strongly bind human serum albumin 
(HSA), we prepared peptide-HSA conjugates (called 
N1-, N3-, Iso1-, and Iso3-HSA) using sulfosuccinimidyl- 
4-[N-maleimidomethyl]cyclohexane-1-carboxylate  
(sulfo-SMCC) as a bifunctional cross-linker, and used 
these conjugates for nanogold functionalization. In 
parallel, we prepared a sulfo-SMCC-activated HSA 
lacking the targeting peptide (called *HSA) as a control. 
Analytical gel-filtration high-performance liquid 
chromatography and mass spectrometry showed  
that all peptide-albumin conjugates consisted of 
monomeric albumin modified with 5–6 linkers and 
2–6 peptide molecules (Figs. S4(a) and S4(b) in the  
ESM). Integrin binding assays showed no binding of 
N1- and N3-HSA to αvβ3, even at concentrations of 
3,000 nM, whereas Iso1-HSA and Iso3-HSA could bind 
αvβ3 with Ki values of approximately 5 nM (Table 1). 
These data suggest that isoDGR contaminants in  
the NGR conjugates were <0.1%. However, N1- and 
N3-HSA, after forced deamidation in ammonium 
bicarbonate buffer (16 h at 37 °C), could bind αvβ3 
with Ki values of approximately 5 nM (Table 1), similar 
to the isoDGR counterparts. Furthermore, when we 
performed deamidation studies in cell culture medium 
(Dulbecco’s modified Eagle medium, DMEM) at 37 °C, 
i.e., in physiological conditions, we observed that the 
 
Figure 2 Effect of NGR peptides with different molecular scaffolds on CD13 enzymatic activity. Recombinant human histidine-tagged 
CD13 (200 ng/mL) was mixed with different amounts of peptides. The mixture were then added to a solution containing the L-alanine 
p-nitroanilide substrate and incubated for 30 min ((a) and (b)) at 37 °C, or 5 min at room temperature (c). The formation of p-nitroanilide 
product was quantified spectrophotometrically (A405 nm). (a) and (b) Representative experiments (n = 2–3) are shown (mean ± SE). 
See also Table S2 in the ESM. (c) Steady state kinetic analysis of CD13 in the presence of various amounts of L-alanine p-nitroanilide 
substrate and N1, N3, or NGR-2C peptide. Representative plots of initial velocity (V0) versus substrate concentration ((c), upper panels) 
and double reciprocal plot ((c), lower panels) (mean ± SE, in quadruplicate). The inhibitory constant (Ki) reported in the plot is the result 
of two independent experiments (mean ± SE). 
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half-lives of N1- and N3-HSA were 10 and 15 h, 
respectively (Fig. S4(c) in the ESM). These data indicate 
that no significant deamidation occurred during con-
jugate preparation and that significant deamidation 
may occur during lengthy in vitro or in vivo assays. 
Thus, the potential transition of NGR to isoDGR 
during assay incubation was taken into account in all 
subsequent studies. 
To assess the capability of NGR peptide-albumin 
conjugates to recognize CD13 on cell membranes, we 
analyzed the interactions of each conjugate (labeled 
with the fluorescent compound IRDye 680) with human 
umbilical vein endothelial cells (HUVECs) and human 
breast adenocarcinoma cells (MCF-7), i.e., with CD13- 
positive and -negative cells. Based on a preliminary 
characterization of these cells by a FACS analysis 
with specific antibodies; HUVECs were CD13+, αvβ3+, 
αvβ5+, and α5β1+, whereas MCF7 cells were CD13–, 
αvβ3–, αvβ5+, and α5β1+ (Fig. 3(a)). 
Interestingly, cell binding assays with fluorescent 
conjugates showed that N1-HSA (140 nM) could 
weakly bind HUVECs (CD13+), but not MCF-7 cells 
(CD13–) (Fig. 3(b)). In contrast, N3-HSA (140 nM) could 
bind both cell lines (Fig. 3(b)). The unexpected binding 
of 140 nM N3-HSA to CD13– cells likely accounted 
for isoDGR formation during the assay, as suggested 
by the observation that Iso3-HSA (the deamidation 
product of N3-HSA) could significantly bind MCF-7 
cells, even at sub-nanomolar levels (Fig. 3(c)). Indeed, 
considering the rapid deamidation kinetics of N3 in 
cell culture medium (see above), it is very likely that 
the nonspecific binding of 140 nM N3-HSA to CD13– 
cells was related to the formation of 1%–2% Iso3-HSA 
during assay incubation; it is a high-affinity ligand of 
αvβ5 and α5β1 (see Table 1 for integrin binding 
affinity), both of which are expressed by MCF-7 cells. 
In contrast, Iso1-HSA could bind MCF-7 cells only at 
concentrations of >50 nM (Fig. 3(c)), likely owing to 
its low affinity for αvβ5 and α5β1 (Table 1) and the 
lack of αvβ3 on these cells.  
These data suggest that N1- and N3-HSA generate 
degradation products with different integrin receptor 
affinities and specificities, which may confound the 
interpretation of NGR interactions with membrane 
CD13. Thus, to clarify this point, we performed 
additional binding experiments using human acute 
lymphoblastic leukemia cells (MOLT-4), a cell line that 
does not express αvβ3-integrin (not shown), transfected 
with or without human CD13 cDNA (CD13/MOLT-4). 
Although a FACS analysis clearly showed the 
expression of CD13 by the transfected cells (Fig. S5(a) 
in the ESM), no binding was observed with 140 nM 
Table 1 Binding of N1-, N3-, Iso1-, and Iso3-HSA to different integrins as measured by a competitive binding assay using a 
CisoDGRC-HRP conjugate 
Competitive binding (Ki a values in nM) to 
v3  v5 v6 v8  51 Competitor 
n b Ki  n Ki n Ki n Ki  n Ki 
N1-HSA 1 >3,000 c     nd d  nd  nd  nd 
N1-HAS (37 °C) e 2 3.9  0.9   nd  nd  nd  nd 
N3-HSA 1 >3,000   nd  nd  nd  nd 
N3-HSA (37 °C) 2 6.1  1.9   nd  nd  nd  nd 





29,086  1875 
(6059)  3
172  29 
(36) 
Iso3-HSA  3 4.7  1.8 (1)  2
7.1  1.6 
(1.5) 3
127  43 
(27) 4
116  4 
(25)  3
39  5.1 
(8.3) 
*HSA 1 >10,000  1 >10,000 1 >10,000 1 >10,000  1 >10,000 
a Ki, equilibrium dissociation constant of the competitor (mean ± SE). Ki was determined using a competitive binding assay as described 
previously [24]. b n, number of independent experiments (each in duplicate). c >, maximum concentration tested that had no inhibitory 
effect. d nd, not determined. e 37 °C, the conjugate was incubated overnight at 37 °C in 0.1 M ammonium bicarbonate buffer, pH 8.5, to 
favor NGR-to-isoDGR conversion. f Relative values to αvβ3 Ki. 
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N1- or N3-HSA/IRDye 680 (Fig. S5(b) in the ESM). 
Higher concentrations could not be tested owing to the 
high levels of nonspecific binding of albumin to both 
cell lines. These data clearly show that low (nanomolar) 
concentrations of NGR cannot bind the CD13 expressed 
by these cells in vitro.  
This finding is consistent with the results of previous 
studies showing that NGR can recognize with high 
affinity a CD13 form expressed by the endothelium 
of tumor vessels, and not (or less efficiently) CD13 
expressed by other tissues, which is an important 
pre-requisite for efficient and selective tumor vascular 
targeting. To verify that low concentrations of N1 can 
indeed interact with endothelial cells in tumors, we 
injected 20 μg of N1-HSA/IRDye 680 or *HSA/IRDye 
680 to mice bearing WEHI-164 fibrosarcomas (a dose 
that generates 100–200 nM peak levels) and analyzed 
their binding to tumors, spleens, and kidneys by a 
fluorescence analysis after organ explantation. Both 
conjugates accumulated in tumors and, to a lesser 
extent, in the spleen and kidney (Figs. 4(a) and 4(b)).  
Significantly higher N1-HSA/IRDye 680 binding 
than HSA/IRDye 680 binding was observed in 
tumors, but not in the spleen or kidney, two CD13-rich 
organs. A FACS analysis of tumor cells after tissue 
disaggregation showed an increased accumulation 
on CD31+CD45– cells (endothelial cells), but not on 
CD31–CD45– (tumor cells) or CD45+ cells (leukocytes) 
(Fig. 4(c)). Notably, the relative staining of endothelial 
cells/leukocytes was significantly higher for N1-HSA/ 
IRDye 680 than controls, but not for *HSA/IRDye 680 
compared to controls (Fig. 4(d)). These results suggest 
that low concentrations of N1-HSA can indeed interact 
with endothelial cells in tumors.  
 
Figure 3 Binding of N1-, Iso1-, N3-, and Iso3-HSA to HUVECs and MCF-7. (a) Expression of CD13, αvβ3, αvβ5, and α5β1 by 
HUVECs and MCF-7 cells, as evaluated by a FACS analysis using the indicated mouse monoclonal antibody, followed by AlexaFluor
488-goat anti-mouse IgG polyclonal antibody. (b) and (c) Binding of the indicated peptide-HSA/IRDye 680 conjugate to HUVECs and 
MCF-7 cells. A dose of 140 nM (b) or various amounts (c) of conjugates were added to cell monolayers (grown in 96-well microtiter 
plates) and incubated for 1 h at 37 °C, 5% CO2 (see Experimental section). After washing, fluorescence was measured using an Odyssey
CLx (LI-COR) scanner. In (b), the specific binding of N1- and N3-HSA was obtained by subtracting the binding of *HSA. 
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2.3 Preparation and characterization of peptide- 
tagged gold nanoparticles loaded with TNF 
Bifunctional gold nanoparticles bearing peptide-HSA 
and recombinant murine TNF were then prepared for 
in vivo studies. Gold nanoparticles were tagged with 
peptide-HSA and TNF by incubating colloidal gold 
with mixtures of these compounds. In particular, four 
nanodrugs, called N1/, N3/, Iso1/, and Iso3/Au/TNF, 
were prepared by incubating colloidal gold with TNF 
solutions pre-mixed with N1-, N3-, Iso1-, or Iso3-HSA, 
respectively.  
The size and the aggregation state of each nanodrug 
were characterized by UV–visible (UV–Vis) spectro-
photometry, dynamic light scattering (DLS), trans-
mission electron microscopy (TEM), and zeta-potential 
analyses. The UV–Vis absorption spectra for each 
product showed single peaks at 528–530 nm (Fig. 5(a) 
and a 650 nm/530 nm ratio <0.1 (Table 2), which are 
consistent with products containing small amounts of 
or no aggregates. Furthermore, TEM showed that gold 
nanoparticles had an average diameter of approximately 
25 nm (Fig. 5(b) and Table 2), and a zeta-potential  
analysis showed that all nanodrugs had a similar 
negative charge (Table 2). These results indicate that 
the four nanodrugs had very similar physico-chemical 
properties, and were mono-dispersed. Remarkably, two 
freezing/thawing cycles and lyophilization/resuspension 
did not cause nanoparticle aggregation as determined 
by UV–visible spectrophotometric analysis (not shown).  
The presence of functional TNF on gold nano-
particles was checked by a cytotoxicity assay, as well 
as by anti-TNF antibodies and soluble TNF receptor 2 
(sTNF-R2) binding assays. The presence of functional 
peptides was checked by αvβ3 binding assays (before 
and after forced deamidation for NGR-containing 
drugs). The cytotoxicity assay showed that 1–4 and 
9–16 bioactive TNF molecules/nanoparticle were present 
in conjugates prepared at pH 6.0 and pH 6.5 (Table 2). 
Furthermore, all TNF-bearing nanodrugs could bind 
TNF receptors (sTNF-R2) spotted onto nitrocellulose 
filters, suggesting that the receptor-binding properties 
of TNF were preserved after adsorption on the gold 
surface (Fig. 5(c), left panel). Of note, after 48 h of 
incubation of the TNF-bearing nanodrug, 15% of TNF  
 
Figure 4 Tumor uptake of N1-HSA/IRDye 680 and *HSA/IRDye 680. (a) and (b) WEHI-164 tumor-bearing mice were injected i.v. with
20 µg of N1-HSA/IRDye 680 or *HSA/IRDye 680 or with diluent. After 24 h, tumors, spleen, and kidneys were explanted, weighted, 
and analyzed with an Odyssey scanner to quantify the fluorescence uptake. Cumulative result of 2–3 independent experiments as 
indicated (n, number of mice). (c) Tumors were disaggregated and analyzed by FACS using anti-CD31 and anti-CD45 antibodies (see 
Experimental Section). (d) Ratio between CD31+CD45– and CD45+ cells (endothelial cells/leukocytes). 
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was released in solution (half-life, 10–12 h) (Fig. S6(d) 
in the ESM). Binding studies to αvβ3 spotted onto 
nitrocellulose filters showed that Iso1/ and Iso3/Au/ 
TNF, but not N1/, N3/Au/TNF, and Au/TNF, could 
bind αvβ3, suggesting that no NGR deamidation 
occurred during nanodrug preparation (Fig. 5(c), 
middle panel). However, after forced deamidation, 
both N1/ and N3/Au/TNF could efficiently bind αvβ3, 
suggesting that N1- and N3-HSA conjugates were 
successfully loaded on gold nanoparticles (Fig. 5(c), 
middle panel). Similar results were also obtained when 
v3 was adsorbed onto microtiter plates and the 
binding of each nanodrug was detected using anti- 
TNF antibodies (Fig. 5(d)). Taken together, the above 
results suggest that the bifunctional properties of N1/, 
N3/, Iso1/, and Iso3/Au/TNF were preserved, i.e., ligand 
targeting and TNF activity.  
2.4 Anti-tumor activity of TNF-based nanodrugs 
The in vivo antitumor properties of each nanodrug 
were then investigated using the WEHI-164 fibro-
sarcoma model. In the first set of experiments, 
tumor-bearing mice were treated (i.v.) with a dose of 
nanodrugs equivalent to 5 pg of bioactive TNF, a 
dose that is completely inactive in this model when 
free TNF is used. Interestingly, N1/Au/TNF delayed 
 
Figure 5 Characterization of TNF-based nanodrugs by UV–Vis spectrophotometry, TEM, and binding assays using αvβ3 and 
sTNF-R2. (a) UV–Vis absorption spectra of N1/, N3/, Iso1/, Iso3/Au/TNF, and Au/TNF. Dotted line corresponds to uncoated 25-nm 
gold nanoparticles. (b) A representative microphotograph of each nanodrug. (c) Binding of nanodrugs to sTNF-R2 and αvβ3 spotted 
onto nitrocellulose filters, as detected by silver staining of gold nanoparticles. The binding of N1/ and N3/Au/TNF after heat-treatment 
(37 °C), i.e., after forced deamidation, is also shown (in red). (d) Binding of nanodrugs to αvβ3 adsorbed onto microtiter plates as
detected with anti-TNF antibodies and HRP-labeled secondary antibodies. 
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tumor growth more efficiently than N3/Au/TNF and 
Au/TNF (Fig. 6(a)). The stronger activity of N1/ versus 
N3/Au/TNF is consistent with the CD13 binding 
properties of the peptides observed in vitro, and N1 
was 3–4-fold more efficient than N3 with respect to 
CD13 recognition (Table S2 in the ESM). Furthermore, 
the stronger activity of N1/Au/TNF compared to 
Au/TNF suggests that the peptide-mediated “active” 
targeting mechanism is important for its anti-tumor 
activity. We also observed that 5 pg of Iso1/Au/TNF, 
i.e., the main degradation product of N1/Au/TNF, 
delayed tumor growth to a similar extent or even 
stronger than N1/Au/TNF (Fig. 6(a)), suggesting that 
this degradation product is biologically active. Notably, 
Iso3/Au/TNF was less active then Iso1/Au/TNF.  
Based on dose-escalation studies using nanodrugs 
loaded with 1–4 or with 9–16 TNF molecules/ 
nanoparticle, the dose-response curves for each drug 
tended to be U-shaped (Fig. 6(b)). Similarly, NGR-TNF 
(CNGRCG-TNF fusion protein) showed a U-shaped 
dose-response curve (Fig. 6(b)). We have previously 
demonstrated that the U-shaped dose-response curve 
of NGR-TNF is related to the activation of counter- 
regulatory mechanisms by high doses, such as soluble 
receptor shedding, which inhibits TNF activity [1]. 
The same likely applies to TNF-based nanodrugs. 
Interestingly, nanodrugs with a fewer TNF molecules/ 
nanoparticle were more efficient (Fig. 6(b)), likely 
because a higher number of injected nanoparticles 
was necessary to achieve the same TNF dose and, 
consequently, to increase the active/passive targeting 
effect. No evidence of toxicity, as judged by animal 
weight loss, was observed for any tested dose and 
drug. Remarkably, 1 pg of Iso1/Au/TNF induced anti- 
tumor effects similar to that of 10–20 pg of N1/Au/TNF 
(Fig. 6(b)), suggesting that Iso1 is more efficient than 
N1 with respect to ligand targeting. This observation 
raises the question as to whether N1/Au/TNF activity 
was actually mediated by the in vivo formation of 
Iso1/Au/TNF and integrin targeting, rather than N1/ 
CD13 interactions. To rule out this possibility, we 
performed CD13 neutralization experiments with a) 
the antibody R363, an anti-murine CD13 antibody 
previously used to neutralize the anti-tumor activity 
of NGR-TNF and NGR-IFNgamma [2, 3], and b) with 
an excess of free N1 peptide. The anti-tumor activity 
of N1/Au/TNF was inhibited by co-administration 
with either the R363 or N1 peptide (Figs. 6(c) and 6(d)),  
Table 2 Characterization of TNF-based nanodrugs by UV–Vis spectroscopy, DLS, cytotoxicity assays, TEM, and zeta-potential analyses
UV–Vis b 














(160 µg:16 µg); pH 6.0        
N1/Au/TNF 531 ± 3 59 ± 1.7 0.08 ± 0.02 16.1 –15.9 ± 7.1 1.2 ± 0.2 25.8 ± 1.2 
N3/Au/TNF 531 ± 3 59 ± 0.4 0.09 ± 0.01 17.7 –14.5 ± 6 1.1 ± 0.2 26.2 ± 1.0 
Iso1/Au/TNF 528 ± 1 59 ± 0.7 0.09 ± 0.01 21.6 ± 3.9 –15.2 ± 6.7 3.4 ± 0.7 25.4 ± 1.1 
Iso3/Au/TNF 530 ± 2 59 ± 0.4 0.06 ± 0.01 16.8 nd  2.8 ± 0.4 nd g 
Au/TNF 528 ± 2 58 ± 0.1 0.09 ± 0.01 22.1 –13.1 ± 5.2 3.6 ± 0.7 27.5 ± 1.1 
 (160 µg:32 µg); pH 6.5        
N1/Au/TNF 529 ± 2 57.7 0.09 16.4 –16.7 ± 5.5 9.0 ± 2.9 24.9 ± 1.0 
Iso1/Au/TNF 526 ± 1 58 ± 0.7 0.09 ± 0.03 23.1 –15.6 ± 6.2 16.3 ± 1.4 27.2 ± 1.0 
Uncoated gold 523 ± 2 57 ± 1.2 0.07 ± 0.02 15.5 ± 1.6 nd 0 nd 
a Nanodrugs were prepared by mixing peptide-HSA and TNF at the indicated ratios with 1 mL of gold (pH 6.0 or 6.5, as indicated). 
b λmax, wavelength of peak absorbance; PW 75%, peak-width at 75% of height; mean ± SD. c Mean ± SD of 2 independent analyses. 
d Number of bioactive TNF molecules/nanoparticle, as determined by a cytotoxicity assay [25], mean ± SE (5–8 independent experiments). 
e Particle diameter was obtained by measuring the width of about 30 particles using ImageJ software. Mean ± SE. f Mean ± SD. g nd, not 
determined. 
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suggesting that the main mechanism underlying the 
activity of this nanodrug is indeed related to CD13 
targeting, as originally hypothesized. Finally, to assess 
whether tumor cell targeting was necessary to induce 
anti-tumor effects, we performed an in vivo experiment 
using the RMA lymphoma model, taking advantage 
of the lack of CD13 and αv-integrin expression in 
RMA cells [2, 19]. We observed that 5 pg of N1/Au/ 
TNF, but not Au/TNF, could induce anti-tumor effects, 
suggesting that endothelial cell targeting is likely 
sufficient to induce anti-tumor effects (Fig. S7 in the 
ESM). 
 
Figure 6 Anti-tumor effects of various formulations of TNF (N1/, N3/, Iso1/, Iso3/Au/TNF nanodrugs, TNF, and NGR-TNF) alone 
((a) and (b)) or in combination with the neutralizing anti-CD13 antibody R363 (c) or peptide N1 (d) in the WEHI-164 fibrosarcoma 
model. (a) Anti-tumor effects of intravenous administration of the indicated drugs, at a dose corresponding to 5 pg of bioactive TNF.
Arrows, time of treatment; tumor volumes (mean ± SE, 6 mice/group). (b) Effect of various doses of the indicated nanodrugs (bearing
1–4 or 9–16 bioactive TNF molecules/nanoparticle) on the growth of tumors from day 5 to day 9. Dotted line: normalized tumor 
volumes at day 5. Numbers within the panels indicate the number of mice per dose (cumulative results of 1–7 independent experiments, 
with 6 mice/experiment, mean ± SE). (c) and (d) WEHI-tumor-bearing mice were treated at day 5 with N1/Au/TNF alone, in combination
with mAb R363 (anti-murine CD13), with isotype matched control antibody (IgG2a), or with N1 at the doses indicated in each panel.
Antibodies were given 2.5 h before N1/Au/TNF, whereas N1 was co-administered with N1/Au/TNF. Arrows indicate the day of treatment.
Tumor volumes (mean ± SE). The area under the curve for each mouse was calculated using GraphPad Prism. Differences between 
calculated areas were evaluated by Mann–Whitney tests (6–8 animals per group; **, P < 0.01; *, P < 0.05). 
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3 Discussion 
To tag TNF-bearing gold nanoparticles with a CD13 
ligand, we selected the head-to-tail cyclized exa-peptide 
c(CGNGRG), called N1, which contains a free thiol 
group suitable for nanodrug coupling. The results of 
enzyme binding and inhibition experiments performed 
with recombinant soluble CD13 suggest that this 
peptide binds within, or close to, the active site (Ki = 
12.4 μM) 6–10-fold more efficiently than CNGRC 
(NGR-2C), a reference disulfide-bridged peptide, and 
c(CNGRGG) (N3), a similar head-to-tail cyclized exa- 
peptide. Additionally, in vivo studies performed in 
tumor-bearing mice showed that gold nanoparticles 
coated with N1-HSA, a peptide-albumin conjugate, 
can deliver TNF to tumors more efficiently than 
nanoparticles coated with N3-HSA or with HSA 
alone. Interestingly, the observation that N1-tagged 
nanoparticles can deliver extremely low, yet phar-
macologically active doses of TNF to tumors (e.g., 
5 pg) implies that high-affinity interactions occurred 
between the N1/Au/TNF nanodrug and tumors. 
Furthermore, the finding that this effect was inhibited 
by the co-administration of an excess of N1 points  
to an important role of the N1 ligand in nanodrug 
delivery to tumors. This view is also supported by 
the observation that N1-HSA/IRDye 680, but not HSA/ 
IRDye 680, could bind to the expected targets, i.e., 
CD31+CD45– cells in tumors (endothelial cells). 
The high-affinity interactions of these conjugates 
with tumor tissues cannot be explained by the NGR/ 
CD13 interactions observed in the in vitro experiments, 
which showed binding at micromolar concentrations 
and very weak (or undetectable) interactions at nano-
molar levels. One explanation is that NGR binding 
affinity differs between the CD13 expressed in vivo 
by tumor vessels and the soluble recombinant CD13 
or the CD13 form expressed by cells in our in vitro 
studies. This hypothesis is supported by the results of 
previous studies showing that phage viral particles 
displaying the NGR peptide can bind CD13-positive 
endothelial cells isolated from tumors, but not CD13- 
positive myeloid-derived cells [26]. Other previous 
studies on the NGR bio-distribution have also shown 
that this peptide sequence can efficiently bind CD13  
in tumors, but not (or less efficiently) other CD13- 
positive tissues [15]. The structural determinants of 
the differential binding are unknown. An interesting 
possibility is that conformational changes in different 
tissues, possibly owing to tissue-specific cofactors or 
signaling molecules, results in differential NGR binding 
affinity. Indeed, natural CD13 is a type II membrane 
dimeric glycoprotein with an N-terminal membrane 
anchor, resulting in an arch-like structure on the cell 
surface that may undergo large conformational changes 
because each monomer can assume open or closed 
conformations [27].  
Other receptors expressed by endothelial cells might 
also contribute to the high-avidity interactions of N1/ 
Au/TNF with tumor endothelial cells; for example, 
considering that this nanodrug contains albumin and 
TNF, albumin receptors (such as albondin, gp30, and 
gp18) [28] and membrane TNF receptors (TNF-R1 and 
TNF-R2) could be involved. In any case, the observation 
that N1/Au/TNF is more potent than Au/TNF in tumor 
animal models, and that the anti-CD13 antibody R363 
or an excess of free N1 peptide completely reduces  
its activity to the level of Au/TNF points to a major 
contribution of NGR/CD13 interactions in tumor drug 
delivery. 
Although N1 characterization studies showed no 
binding to integrins at submicromolar concentrations, 
the notion that N1 can deamidate to generate Iso1,  
a high-affinity integrin ligand, and the observation 
that Iso1/Au/TNF acts as a potent nanodrug active  
at picogram doses in our animal models raises the 
question as to whether integrin binding contributes 
to N1-mediated targeted delivery. The marked 
inhibition of N1/Au/TNF by the anti-CD13 antibody 
R363 and by N1 suggests that the main mechanism 
underlying the activity of this nanodrug is related  
to CD13 targeting, as originally hypothesized, and 
not (or minimally) to integrin targeting. In previous 
studies, we have shown that the anti-tumor activity 
of a CNGRC-TNF fusion protein can be inhibited by 
an excess of CNGRC, but not of CisoDGRC (integrin 
ligand), whereas the activity of CisoDGRC-TNF can 
be inhibited by an excess of CisoDGRC, but not of 
CNGRC [19]. These results suggest that the binding 
of NGR to CD13 alone is sufficient for targeting and 
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that the transition to isoDGR and consequent integrin 
recognition is not necessary for the observed activity.  
Another important point is related to the impact  
of the number of TNF molecules/nanoparticles on 
nanodrug activity. Indeed, injecting the same dose  
of TNF formulated as a nanodrug bearing 1–4 or 9–16 
TNF molecules/nanoparticle implies that a different 
number of nanoparticles are injected (e.g., 2–3 × 106 
or 2–3 × 107 nanoparticles, respectively, for a dose of 
5 ng of TNF). This may have important consequences 
on activity, despite equal TNF doses, for the following 
reasons: (1) A higher number of injected nanoparticles 
could reach a higher number of endothelial cells in 
tumors and (2) a lower number of TNF molecules/ 
nanoparticles allows the loading of a higher number 
of peptide-albumin molecules on each nanoparticle, 
thereby increasing the overall targeting efficiency. 
Consistent with this view, we observed stronger 
effects with the nanodrug bearing 1–4 TNF molecules/ 
nanoparticle. 
In conclusion, the results show that the N1 peptide 
has an improved affinity for CD13, is suitable for 
tagging colloidal gold, and (after coupling to nanogold) 
is an efficient carrier for TNF delivery to tumors. The 
favorable CD13-binding properties of N1 may overcome 
some of the problems related to the use of CNGRC as a 
gold-tagging peptide. Indeed, in the case of CNGRC, 
disulfide-gold interactions and disulfide exchange 
between adjacent peptides may occur in multivalent 
nanoparticles, thereby altering or hindering the NGR 
structure [29, 30]. N1 overcomes this problem because 
cyclization is obtained via head-to-tail peptide bonds 
and not via cystine. Finally, the development of N1/ 
Au/TNF overcomes a major obstacle in the use of TNF 
in patients, i.e., its low therapeutic index. Indeed, the 
clinical use of TNF is currently limited to loco-regional 
treatments in patients with sarcomas localized at the 
extremities owing to the prohibitive systemic toxicity. 
As no toxic reactions were observed in mice treated 
intravenously with extremely low doses of N1/Au/ 
TNF, this drug formulation could enable, in principle, 
systemic treatments of cancer patients with solid 
tumors. N1-tagged nanogold could potentially be loaded 
with other synergistic cytokines (e.g., IFN-gamma or 
EMAP-2), thereby enabling multicytokine delivery to 
endothelial cells in tumors.  
4 Experimental 
4.1 Cell lines and reagents 
MCF-7 and murine WEHI-164 fibrosarcoma cells were 
cultured in DMEM supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 50 μg/mL streptomycin, 
100 U/mL penicillin, and 0.25 μg/mL amphotericin-B. 
HUVECs were cultured in endothelial cell growth 
medium (EGM)-2 (Lonza, Walkersville, MD, USA). 
MOLT-4 cells (acute lymphoblastic leukemia) trans-
fected with human CD13 cDNA (CD13/MOLT-4) were 
prepared and cultured as described previously [15]. 
Sulfo-SMCC was obtained from Pierce (Rockford, 
IL, USA), HSA was obtained from Baxter (Deerfield, 
IL, USA), and bovine serum albumin (BSA) was 
obtained from Sigma (St. Louis, MO, USA).  
Murine tumor necrosis factor-alpha (TNFα) was 
prepared as described previously [25]. TNF was 
dialyzed against 5 mM citrate buffer, pH 6.0 and stored 
in aliquots at –20 °C. 
NGR-TNF (consisting of TNF fused with the C- 
terminus of CNGRCG) was prepared by recombinant 
DNA technology and purified from Escherichia coli 
cell extracts as described previously [2]. 
Human αvβ3, αvβ5, and α5β1 integrins were 
obtained from Immunological Sciences (Rome, Italy); 
recombinant human αvβ6 and αvβ8 integrins were 
obtained from R&D Systems (Minneapolis, MN, USA). 
Monoclonal antibodies WM15 and R363 (anti-human 
and -mouse CD13, respectively) were obtained from 
Acris Antibodies (San Diego, CA, USA), LM609, 
P1D6, and P1D5 (anti-human αvβ3, αvβ5, and α5β1, 
respectively) were obtained from Immunological 
Sciences (Rome, Italy), and rat IgG2a isotype control 
antibody was obtained from BioLegend (San Diego, 
CA, USA). 
4.2 Peptide synthesis and characterization 
Head-to-tail cyclic peptides (see Fig. 1 for schematic 
representations of each peptide and peptide code) 
were prepared by the solid-phase Fmoc method [31]. 
Disulfide-bridged NGR peptide was prepared as 
described previously [18]. All peptides were dissolved 
in water and stored in aliquots at –20 °C. The molecular 
mass of each peptide was checked by MALDI-TOF 
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mass spectrometry (see Table S1 in the ESM). Thiol- 
containing peptides were quantified using the Ellman’s 
assay.  
4.3 CD13 enzymatic activity assay and CD13 com-
petitive binding assay 
For the CD13 enzymatic activity assay, 96-well PVC 
microtiter plates were filled with a mixture of 
recombinant human His-tagged CD13 (0.2 μg/mL, Sino 
Biological Inc., Beijing, China), L-alanine-p-nitroanilide 
(0.5 mM; Sigma) and various amounts of peptide in 
60 mM potassium phosphate buffer, pH 7.4 (100 μL/ 
well, final volume). The mixtures were then incubated 
for 30 min at 37 °C. The absorbance at 405 nm of the 
p-nitroanilide product was measured using an enzyme- 
linked immunosorbent assay microtiter plate reader. 
The IC50 was calculated by a non-linear regression 
analysis of competitive inhibition data using GraphPad 
Prism (GraphPad Software, Version 6.00; San Diego, 
CA, USA). 
Steady-state enzyme kinetic analyses were per-
formed at room temperature (23 °C) in 96-well plates 
as described above, using increasing concentrations 
of L-alanine-p-nitroanilide (100–1,000 μM), at fixed 
concentrations of N1 ranging from 0 to 100 μM. The 
initial velocities (V0) were calculated from the slopes 
of the first 5 min of the reaction. The enzyme inhibitory 
constants (Ki) were calculated using the Competitive 
enzyme inhibition model of GraphPad Prism (GraphPad 
Software, Version 6.00). 
A CD13 competitive binding assay with peptides 
was performed using microtiter plates coated with the 
anti-CD13 monoclonal antibody WM15 and His-tagged 
recombinant CD13 as described in the ESM. 
4.4 Preparation of peptide-HSA conjugates and 
characterization of their CD13 and integrin binding 
properties 
Peptide N1, N3-, Iso1-, and Iso3- were coupled to 
HSA as follows: HSA, 40 mg in 380 μL of 10 mM 
phosphate buffer, 138 mM sodium chloride, 2.7 mM 
potassium chloride, pH 7.4, containing 5 mM EDTA 
(PBS-E) was mixed with sulfo-SMCC (2.4 mg in 120 μL 
in water) and left to react for 1 h at room temperature.  
Then, the mixture was purified by gel-filtration 
chromatography on a NAP-5 column (GE Healthcare 
Life Sciences, Little Chalfont, UK), pre-equilibrated 
with PBS-E. Aliquots of activated-HSA (20 mg) were 
mixed with various peptides (1.5 mg, 9:1 peptide/HSA 
molar ratio) and reacted for 3 h. Then, 2-mercaptoethanol 
was added (1 mM, final concentration) and incubated 
for 0.5 h. The conjugates were gel-filtered through a 
PD10 column (GE Healthcare Life Sciences) pre- 
equilibrated with 10 mM phosphate buffer, 138 mM 
sodium chloride, 2.7 mM potassium chloride, pH 7.4, 
and stored at –20 °C. The protein concentration in 
each conjugate was determined spectrophotometrically 
(A280 nm). 
The binding of peptide-HSA to cells was performed 
as follows: First peptide-HSA conjugates were labeled 
with the IRDye 680 RD-NHS-ester dye (LI-COR, 
Lincoln, NE, USA) by incubating mixtures of 590 μL 
of each conjugate (1.350 mg in of 25 mM Hepes, 
containing 150 mM NaCl, pH 7.4 (Hepes buffer) with 
90 μL of dye (2 mg/mL in dimethyl sulfoxide, 9:1 dye 
to HSA molar ratio) for 4 h at 4 °C, and blocking with 
1 M glycine (50 mM, final concentration, for 0.5 h). The 
conjugates were then dialyzed extensively against 
Hepes buffer (10 kDa, cut-off) and stored at –80 °C.  
The binding of peptide-HSA/IRDye 680 conjugates 
to HT-1080, HUVECs, and MCF-7 cells was then 
analyzed as follows. The cells were grown in 96-well 
clear-bottom black plates (2–3 × 104 cells/well, plated 
48 h before the experiment). After washing with DMEM 
containing 1% fetal bovine serum and 3 mg/mL HSA 
(binding buffer), each conjugate (0.2–150 nM in binding 
buffer) was added to the cells, followed by incubation 
for 1 h at 37 °C, 5% CO2. After three washings with 
binding buffer (3 min each), the cells were fixed with 
PBS containing 2% paraformaldehyde and 3% sucrose 
for 15 min at room temperature. Binding of conjugates 
to cells was quantified by scanning the plate with an 
Odyssey CLx (LI-COR). Then, the cells were coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI, 
a nuclear stain) and the plates were analyzed using  
a VICTOR3 (Perkin Elmer, Waltham, MA, USA) 
fluorescence plate reader to quantify the cell number 
in each well.  
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4.5 Quantification of N1-HSA/IRDye 680 conjugate 
uptake in tumors and tumor cell suspensions 
WEHI-164 tumor-bearing mice were treated i.v. with 
20 μg of N1-HSA/IRDye 680 or *HSA/IRDye 680 or 
with diluent. After 24 h, the tumor, spleen and kidney 
were collected and analyzed with an Odyssey CLx 
scanner to assess the uptake of fluorescence (settings: 
2 mm; 1.5 intensity; 700-nm filter). Then, tumors were 
minced, resuspended with a collagenase-D solution in 
RPMI medium (1 mg/mL, 3 mL/g tumor tissue, Roche, 
Basel, Switzerland) and incubated for 1 h at 37 °C 
under gentle agitation. Cell suspensions were filtered 
through a 70-μm nylon cell-strainer and centrifuged. 
The pellets were resuspended in PBS containing 2% 
FCS, Fc-blocking solution (5 μg/mL, BD Biosciences, 
Franklin Lakes, NJ, USA) and incubated for 10 min  
at room temperature. After washing, the cells were 
incubated with the fluorescence labeled-monoclonal 
antibodies anti-CD45-V500 (2 μg/mL, clone, 30-F11, 
BD Biosciences) and anti-CD31-FITC (2.5 μg/mL, clone, 
MEC 13.3; BioLegend, San Diego, CA, USA), both in 
PBS containing 2% FCS (15 min at room temperature). 
After washing, the cells were incubated with the dye 
7AAD (2.5 μg/mL, BD Biosciences), a marker of dead 
cells, and analyzed by FACS. At least 100,000 cells/ 
sample were acquired with a FACS Fortessa system 
equipped FACSDiva software (BD Biosciences). 
Fluorescence minus-one (FMO) controls were used  
to gate marker-positive cells. Percentages of stained 
cells were determined using FlowJo software. 
4.6 Preparation of gold nanoparticles functionalized 
with NGR or isoDGR peptides and TNF 
Bifunctional gold nanoparticles bearing peptide-HSA 
and recombinant murine TNF were prepared by 
incubating colloidal gold (25 nm; Aurion, The Nether-
lands) with a TNF solution pre-mixed with N1-, N3-, 
Iso1-, or Iso3-HSA with the pH of colloidal gold 
adjusted to 6.0 or 6.5 with 200 mM sodium citrate 
buffer (100/1 volume ratio). In particular, two protein 
combination ratios were added to 1 mL of colloidal 
gold: a) 160 μg of peptide-HSA and 16 μg of TNF with 
gold pH adjusted to 6.0 and b) 160 μg of peptide-HSA 
and 32 μg of TNF with gold pH adjusted to 6.5. These 
ratios were chosen based on the results of preliminary  
studies performed to identify the concentrations  
that generate nanodrugs with optimal bifunctional 
properties and stability (Fig. S6 in the ESM). Mixtures 
were incubated for 1 h at room temperature under 
shaking. Then, 100 μL of mPEG-SH solution (15 μg/mL 
in water, MW = 20,000, NANOCS) was added to the 
mixture and incubated for 15 min at room temperature. 
Finally, 28 μL of a 10% HAS solution was added to 
saturate the gold nanoparticles. The mixtures were 
centrifuged twice (12,000 × g for 10 min). The final 
products were resuspended with 5 mM sodium citrate 
buffer, pH 6.0, containing 1% HSA to a final volume 
of 1 mL and stored at –80 °C. Nanoparticles bearing 
*HSA (lacking the targeting peptide) and TNF were 
also prepared (Au/TNF).  
4.7 Characterization of the physicochemical  
properties of nanodrugs 
The physicochemical properties of each nanodrug 
were characterized by UV–Vis spectrophotometry, 
DSL, TEM, and zeta-potential analyses as described 
in the ESM.  
4.8 Characterization of the functional properties 
of nanodrugs 
The number of bioactive TNF molecules loaded  
onto the nanoparticles was determined by a murine 
fibroblast LM cytotoxicity assay [25].  
The binding of nanodrugs, before and after 
incubation at 37 °C in 0.1 M ammonium bicarbonate 
buffer, pH 8.5, to sTNF-R2 and αvβ3 spotted on 
nitrocellulose filters was performed as described 
previously [24]. 
The binding of nanodrugs to microtiter plates coated 
with αvβ3 as was performed as follows. Human αvβ3 
integrin solution and 0.5 μg/mL in PBS with Ca2+ and 
Mg2+ (DPBS; Cambrex, East Rutherford, NJ, USA) 
were added to 96-well microtiter plates (Falcon 3912, 
Becton Dickinson, 50 μL/well) and incubated overnight 
at 4 °C. All subsequent steps were carried out at room 
temperature. The plates were washed with DPBS  
and further incubated with DPBS containing 3% 
BSA (200 μL/well; 1 h). The plates were washed with 
25 mM Tris-HCl, 150 mM sodium chloride, 1 mM 
magnesium chloride, 1 mM manganese chloride (pH  
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7.4; washing solution), and filled with serial dilutions 
of the nanodrug solution (50 μL/well in washing 
solution containing 1% BSA, binding buffer). After 
incubation for 2 h, the plates were washed again and 
incubated with a rabbit polyclonal anti-TNF serum 
(IP301) diluted in binding buffer (1:1,000, 50 μL/well, 
1.5 h) followed by a goat anti-rabbit peroxidase 
conjugate diluted in the same buffer (1:1,000, 50 μL/ 
well, 1 h). Bound peroxidase was detected by adding 
o-phenylenediamine chromogenic substrate (70 μL/ 
well). 
4.9 Characterization of the pharmacological and 
toxicological properties of nanodrugs 
Studies in animal models were approved by the Ethical 
Committee of the San Raffaele Scientific Institute, and 
performed according to the prescribed guidelines. 
BALB/c female mice (6–7 weeks old; Charles River 
Laboratories, Calco, Italy) were challenged with 
subcutaneous injections in the left flank of 1.5 × 106 
WEHI-164 cells. Mice were injected, i.v., with nano-
drugs diluted with 0.9% sodium chloride containing 
100 μg/mL HSA. Tumor growth was monitored by 
measuring tumor size with calipers. The tumor volume 
was estimated by calculating r1 × r2 × r3 × 4/3π, 
where r1 and r2 are the longitudinal and lateral radii, 
and r3 is the thickness of the tumor protruding from 
the surface of normal skin. Animals were sacrificed 
before tumors reached a diameter of 1.0 to 1.5 cm. 
Tumor sizes are shown as means ± SE. 
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